Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 11Carcinoma, Hepatocellular 7Colorectal Neoplasms 5Neoplasm Metastasis 4Esophageal Squamous Cell Carcinoma 4Advanced Solid Tumor 4Solid Tumor 3Small Cell Lung Carcinoma 3Esophageal Neoplasms 3Stomach Neoplasms 2Squamous Cell Carcinoma of Head and Neck 2Recurrence 2Melanoma 2Lung Neoplasms 2Cholangiocarcinoma 2Carcinoma, Transitional Cell 2Advanced Solid Tumour 2Unresectable Stage III Non-small Cell Lung Cancer 1Triple Negative Breast Neoplasms 1Skin Neoplasms 1Simpson-Golabi-Behmel syndrome 1Rectal Neoplasms 1Patients With Initially Unresectable MSS-type Advanced Colorectal Cancer With Liver and/or Lung and Peritoneal Metastasis 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Pancreatic Neoplasms 1Neoplasms 1Neoplasm, Residual 1Nasopharyngeal Carcinoma 1Metastatic Solid Tumors 1MSI-H/dMMR Solid Tumors 1

Interventions

Midazolam 2zanidatamab 1tislelizumab 1sitravatinib 1repaglinide 1pamiparib 1lenvatinib 1drospirenone 1Temozolomide 1HMPL-013 1Ethinyl Estradiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced Malignancies × tislelizumab × 90 days × Clear all
NCT04164199 2026-06-03

Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With Advanced Malignancies

BeOne Medicines

Phase 3 Completed
404 enrolled

Advanced Malignancies

Data powered by HemOnc (CC BY 4.0) Colophon âš¡